A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

NCT03149003 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

221

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma

Interventions

DRUG: DSP-7888 Dosing Emulsion
DRUG: Bevacizumab

Sponsor

Sumitomo Pharma America, Inc.